Dana–Farber Cancer Institute

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, August 12, 2022 - 1:00pm
FDA, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Risk, GLOBE, ORR, Health care, Population, Fortress Biotech, European Medicines Agency, Private Securities Litigation Reform Act, Clinical trial, Securities Exchange Act of 1934, Patent, Society, Research, Annual report, Biologics license application, Pemetrexed, Patient, Marketing, COVID-19, Company, CSCC, D, EGFR, Acquisition, Data, NASDAQ, Chemistry, Dana–Farber Cancer Institute, BLA, Securities Act of 1933, CMC, Platinum, Regulation, CKPT, Pharmaceutical industry, Lithium

WALTHAM, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights.

Key Points: 
  • WALTHAM, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights.
  • In May 2022, Checkpoint announced that it received Pediatric Investigation Plan product-specific waivers from the European Medicines Agency and the U.K.
  • General and administrative expenses for the second quarter of 2022 included $0.5 million of non-cash stock expenses, compared to $0.9 million for the second quarter of 2021.
  • Net loss for the second quarter of 2022 included $0.7 million of non-cash stock expenses, compared to $1.0 million for the second quarter of 2021.

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

Retrieved on: 
Friday, August 12, 2022 - 12:00pm
Hospital, ASCO, BeiGene, CEO, NewYork-Presbyterian Hospital, American Society of Clinical Oncology, Division, Dana–Farber Cancer Institute, SEC, Leadership, Cancer, National academy, Board, Director, LLC, Colorectal Cancer Alliance, Cancer Breakthroughs 2020, Clinical trial, Brigham and Women's Hospital, EDGAR, Patient, Therapy, NCI, Harvard Medical School, Surgical oncology, DKK1, Weill Cornell Medicine, National Academy of Medicine, National Cancer Institute, Alliance for Clinical Trials in Oncology, Nasdaq, MD, National, Dana, Pharmaceutical industry, LEAP

CAMBRIDGE, Mass., Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics today announced that its Board member, Monica Bertagnolli, MD, has been appointed as the 16th Director of the National Cancer Institute (NCI) by the Biden administration. Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937. Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.

Key Points: 
  • Dr. Bertagnolli becomes the first woman director of the institute since its inception in 1937.
  • Effective with her appointment, Dr. Bertagnolli will transition off Leap's Board of Directors.
  • Dr. Bertagnolli is currently a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women's Hospital and Dana-Farber Cancer Institute.
  • Dr. Bertagnolli has served on numerous committees and boards including the Board of Directors for ASCO and the National Academy of Medicine's National Cancer Policy Forum.

There's a Better Way to Detect High-Risk Medications in Older Adults with Cancer According to New Study in JNCCN

Retrieved on: 
Wednesday, August 10, 2022 - 9:02pm
Cancer, Geriatrics, Research, Harborside, National Comprehensive Cancer Network, Brigham and Women's Hospital, Patient, Education, Weakness, Lymphatic system, Overalls, Health, Risk, Comorbidity, Dana–Farber Cancer Institute, Policy, PIMS, Frailty, Report, Public policy, Weight loss, Hospital, NCCN, Caregiver, Benzodiazepine, Harvard Medical School, Ageing, Journal of the National Comprehensive Cancer Network, Decision-making, Cone Health Women's Hospital, Association, Bioethics, Roswell Park Comprehensive Cancer Center, Selective serotonin reuptake inhibitor, Cognition, Review, Twitter, Strathcona County, MPH, Oncology, Medicine, Dietary supplement, Medical imaging, Polypharmacy, MD, Brigham

PLYMOUTH MEETING, Pa., Aug. 10, 2022 /PRNewswire/ -- A new study in the August 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women's Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.

Key Points: 
  • "A large portion of research for older adults identifies patients as 'having polypharmacy' (i.e.
  • "We were interested in the NCCN list of medications of concern because, in contrast to other lists, it was developed by geriatricians and oncologists to be specific for older adults with cancer.
  • "Additional studies are warranted to better define the optimal utilization of this scale and its potential benefits for older adults with cancer."
  • Complimentary access to " The Association of Polypharmacy and Potentially Inappropriate Medications with Frailty among Older Adults with Blood Cancer " is available until November 10, 2022.

The Cancer Support Community Applauds the Appointment of Dr. Monica Bertagnolli to Director of the National Cancer Institute

Retrieved on: 
Wednesday, August 10, 2022 - 6:15pm
Hospital, Cancer Support Community, CEO, GLOBE, Division, Dana–Farber Cancer Institute, Clinical trial, Leadership, Cancer, Learning, Cancer Breakthroughs 2020, Society, Knowledge, Research, American Society of Clinical Oncology, Patient, Health policy, NCI, Harvard Medical School, International Food Protection Training Institute, United Nations International Research and Training Institute for the Advancement of Women, DARPA, Surgical oncology, CSC, Science, National Cancer Institute, MD, Public policy, National, Medicine, Brigham

WASHINGTON, D.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) enthusiastically supports President Bidens selection of Monica Bertagnolli, MD to the position of director of the National Cancer Institute (NCI).

Key Points: 
  • WASHINGTON, D.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) enthusiastically supports President Bidens selection of Monica Bertagnolli, MD to the position of director of the National Cancer Institute (NCI).
  • Bertagnolli is a professor of surgery at Harvard Medical School and serves as chief of the Division of Surgical Oncology at Brigham and Womens Hospital and Dana-Farber Cancer Institute.
  • CSC anticipates fruitful collaboration with Dr. Bertagnolli and the NCI moving forward, ushering in an exciting period of cancer research.
  • CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington, D.C. and across the nation.

DCG Giving, a Dave Cantin Group Nonprofit, Partners with Children’s Oncology Group to Fight Pediatric Cancer and Support Cutting-Edge Research and Treatment

Retrieved on: 
Wednesday, August 10, 2022 - 3:16pm
Finance, Consulting, Professional Services, Philanthropy, Other Health, Health, Foundation, Other Philanthropy, Oncology, Other Professional Services, Children's Oncology Group, Hospital, Organic, Children's Hospital Los Angeles, Mergers and acquisitions, St. Jude Children's Research Hospital, Industry, Children's Hospital of Philadelphia, Adolescence, Memorial Sloan Kettering Cancer Center, Research, Organization, DCG, Cincinnati Children's Hospital Medical Center, Patient, Institute for Mergers, Acquisitions and Alliances, Center, Foundation, COG, Johns Hopkins Children's Center, Partnership, Community, Geisinger Medical Center, American Cancer Society, Dana–Farber Cancer Institute, Philadelphia, Seattle Children's, Mobile phone, Birth control, MD, Cancer, Child

Today DCG Giving announced it has entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.

Key Points: 
  • Today DCG Giving announced it has entered a partnership with the Children's Oncology Group (COG) the world's largest organization devoted exclusively to childhood and adolescent cancer research and treatment.
  • The goal of DCG Giving is to offer financial and structural support to COGs local child and adolescent cancer programs and assist patients and their families across the country.
  • We are proud to partner with COG, which is trailblazing the advancement for childhood and adolescent cancer research and treatment, said Executive Director Michael Weiner, MD.
  • The organizations mission is to fund lifesaving child and adolescent cancer research and treatment in communities nationwide.

Survey on Sexual Health Among Women with Lung Cancer Reveals High Levels of Sexual Dysfunction

Retrieved on: 
Tuesday, August 9, 2022 - 1:00pm
Lung cancer, PROMIS, Sexual dysfunction, Diagnosis, Reproductive health, Clinical trial, Dana–Farber Cancer Institute, International Association for the Study of Pain, Research, Health minister, Cancer, Patient, Fatigue, WCLC, Awareness, Lung, IRB, Physician, Patient-Reported Outcomes Measurement Information System, Conference, Personal lubricant, Birth control, Woman

(Vienna, Austria)--According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity. The survey results from the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study were reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Key Points: 
  • According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity.
  • (Vienna, Austria)--According to survey data reported today, sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity.
  • The survey results from the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study were reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • "We report the results of the SHAWL study, the largest study to date evaluating sexual dysfunction in women with lung cancer."

World's Most Successful Bike-a-thon, the Pan-Mass Challenge, Kicks Off 2022 Ride to Raise Record-Breaking $66 Million for Cancer Research

Retrieved on: 
Saturday, August 6, 2022 - 2:30pm
Cancer, Hospital, The Jimmy Fund, M&T Bank, Dana–Farber Cancer Institute, Pan-Mass Challenge, Research, Health, Patient, Instagram, Twitter, Education, PMC, LinkedIn, Volunteering, Efficiency, Adult, NCI-designated Cancer Center, Property management, Pharmaceutical industry, Facebook, MD

BOSTON, Aug. 6, 2022 /PRNewswire/ -- On Saturday, August 6 and Sunday, August 7, the Pan-Mass Challenge (PMC) will bring together more than 6,300 registered riders from around the globe for its 43rd ride with the goal of raising a record-breaking $66 million for cancer research and patient care at the world-renowned Dana-Farber Cancer Institute in Boston, Massachusetts. 

Key Points: 
  • If the PMC achieves its goal of raising $66 million this year, it will bring its total contributions to more than $897 million since 1980.
  • Cyclists from 8 countries and 43 states will participate in this year's ride, many in honor of a family member or friend fighting cancer.
  • The PMC has since raised $831 million for adult and pediatric patient care and cancer research at Dana-Farber Cancer Institute through the Jimmy Fund.
  • Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment.

IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies

Retrieved on: 
Tuesday, August 2, 2022 - 11:30am
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Orphan drug, Neoplasm, De novo, Merck Group, Drug combination, Food, CEO, FACP, Therapeutic index, Cancer, Dana–Farber Cancer Institute, GI, Drug development, FDA, GIST, Disease, Patient, LinkedIn, Precision medicine, Therapy, Harvard Medical School, Sarcoma, Gastrointestinal stromal tumor, Cystic fibrosis, Medicine, Pharmaceutical industry

IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed Series A financing.

Key Points: 
  • IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed Series A financing.
  • The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors.
  • Although precision medicines have revolutionized the treatment of some cancers, tumors can evolve multiple escape mutations, said Alexis Borisy, co-founder of IDRx.
  • Our goal is to build de novo combinations to serve as transformative cancer treatments.

Graham-Pelton names Walt Edwards President

Retrieved on: 
Monday, August 1, 2022 - 5:17pm
Philadelphia, View, University, Case Western Reserve University, Weatherhead School of Management, Rutgers Biomedical and Health Sciences, Talent, H. Lee Moffitt Cancer Center & Research Institute, Industry, Vanderbilt University Medical Center, Training and development, Beth Israel Deaconess Medical Center, Culture, Partnership, Case Western Reserve University School of Law, Multimedia, The Ride to Conquer Cancer, Hospital, Assistant, Emory Healthcare, Dana–Farber Cancer Institute, Children's Hospital of Orange County, Leadership, Moses Austin, Children's Hospital of Philadelphia, Orange County, Colby College, Growth, USF Health Byrd Alzheimer's Institute, University of Pennsylvania Health System, Pharmaceutical industry, Interior design, Management, Collegium (ancient Rome)

NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Leading global fundraising consulting firm Graham-Pelton announced today the appointment of Walt Edwards as its president.

Key Points: 
  • NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Leading global fundraising consulting firm Graham-Pelton announced today the appointment of Walt Edwards as its president.
  • Leading global fundraising consulting firm Graham-Pelton announces the appointment of Walt Edwards as its president.
  • "Walt is the right leader for this next stage in Graham-Pelton's history," said Graham-Pelton founder, Craig Leach.
  • "It's a pleasure to be named president of a firm as globally recognized and distinguished as Graham-Pelton," said Edwards.

SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments

Retrieved on: 
Thursday, July 28, 2022 - 12:00pm
Knowledge, CLIA, GLOBE, Oncology, Physician, Colon, Series, Drug discovery, Partnership, 3D, Precision, Lung, Fred Hutchinson Cancer Research Center, Technology, 2020–21 Serie A2 women's basketball season, Company, Patient, Science, Robotics, Cancer, Dana–Farber Cancer Institute, Breast, Pharmaceutical industry, Medical imaging, Fine chemical, Vincere

SEngine's CLIA certified PARISTest generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.

Key Points: 
  • SEngine's CLIA certified PARISTest generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.
  • Investor participation was spurred by the continued momentum of SEngines platform in both drug discovery and clinical diagnostics.
  • SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures utilizing patient specific tumor cells.
  • SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies by deploying its precision oncology platform.